A phase IV multicenter, randomized, double-blind study. prospective study on intensive early rheumatoid arthritis treatment with adalimumab: Induction of remission and maintenance.

Trial Profile

A phase IV multicenter, randomized, double-blind study. prospective study on intensive early rheumatoid arthritis treatment with adalimumab: Induction of remission and maintenance.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Adalimumab (Primary) ; Methotrexate; Prednisone
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms CURE
  • Most Recent Events

    • 17 Jun 2017 Primary endpoint has not been met. (to evaluate the proportion of subjects who achieve remission at week 52 after treatment, as defined by DAS 28 less than or =2.6) as per results presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
    • 28 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top